Global Fibrinogen Concentrates Market Size was USD 1.06 Billion in 2025, this report covers Market growth, trend, opportunity and forecast from 2026-2032

The Fibrinogen Concentrates market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.

1. CSL Behring:

   CSL Behring holds a dominant role in the global fibrinogen concentrates market, leveraging its deep plasma-fractionation expertise and broad hemostasis portfolio. The company is positioned as a reference supplier for hospital transfusion services and trauma centers that prioritize standardized dosing, pathogen safety, and consistent supply reliability. Its presence in North America, Europe, and Asia-Pacific allows it to shape clinical practice guidelines and tender specifications, which reinforces its leadership role and influences formulary decisions across tertiary care networks.

   In 2025, CSL Behring’s fibrinogen concentrates business is projected to generate revenue of USD 0.28 Billion with an estimated market share of 26.50% . These figures indicate that CSL captures more than a quarter of the anticipated USD 1,06 Billion global market size in 2025 as reported by ReportMines. This scale demonstrates strong purchasing leverage in plasma sourcing, favorable contract terms with hospital groups, and a significant advantage in funding large-scale post-marketing clinical trials that reinforce product adoption.

   CSL Behring’s strategic advantages stem from its integrated plasma collection infrastructure, continuous investments in pathogen reduction technologies, and a robust regulatory track record with agencies in the United States, European Union, and key emerging markets. The company differentiates itself through comprehensive medical education programs targeting hematologists, anesthesiologists, and trauma surgeons, which enhances guideline inclusion and supports protocol-based use of fibrinogen concentrates over cryoprecipitate. Compared with smaller peers, CSL’s broad pipeline in rare bleeding disorders and immunology also allows it to bundle contracts and secure preferred supplier status within large hospital networks.

2. Octapharma AG:

   Octapharma AG is a major global competitor in fibrinogen concentrates, with a strong presence in Europe and growing penetration in North America and selected Asia-Pacific markets. The company is recognized for its focus on high-purity plasma-derived therapies, including fibrinogen concentrates used in congenital fibrinogen deficiency and acquired bleeding scenarios in cardiac surgery and obstetrics. Its manufacturing footprint in Europe supports efficient supply into both public tenders and private hospital chains.

   For 2025, Octapharma’s fibrinogen concentrates revenue is estimated at USD 0.17 Billion with a market share of approximately 16.00% . This performance positions Octapharma as one of the top-tier suppliers, capturing a significant portion of the ReportMines-defined 2025 market while still trailing the scale of the largest incumbent. The revenue base provides sufficient cash flow to support incremental capacity expansions, next-generation formulation work, and risk-mitigation investments in plasma sourcing.

   Octapharma’s core competitive strengths include flexible manufacturing, strong relationships with European blood services, and a reputation for stringent quality control. The company differentiates itself via product stability, vial size options that match surgical dosing patterns, and a responsive approach to hospital-level shortages. Compared with some larger multinational pharmaceutical companies, Octapharma is more focused on plasma therapies, which allows it to prioritize fibrinogen concentrates in its strategic roadmap and retain organizational agility when adapting to evolving reimbursement frameworks and clinical guidelines.

3. Grifols S.A.:

   Grifols S.A. is a key player in the fibrinogen concentrates landscape, benefiting from its significant global network of plasma collection centers and advanced fractionation facilities. The company’s hemostasis portfolio supports a broad range of bleeding indications, and its fibrinogen products are especially relevant in European markets and parts of Latin America. Grifols leverages cross-selling opportunities with its immunoglobulin and albumin lines, strengthening bargaining power with hospital procurement departments.

   In 2025, Grifols’ fibrinogen concentrates segment is projected to deliver revenue of USD 0.13 Billion and an estimated market share of 12.30% . These figures indicate a solidly entrenched position within the market, though not at the scale of the top two players. The revenue contribution, while representing a smaller share of Grifols’ broader plasma portfolio, is strategically important because it enhances the company’s overall hemostasis offering and helps justify continued capacity investments in specialized fractionation steps.

   Grifols’ strategic advantages include vertical integration from plasma collection to finished products, advanced pathogen inactivation technologies, and an expanding presence in the United States. The company also invests in real-world evidence and registry data to showcase clinical outcomes when fibrinogen concentrates replace cryoprecipitate in trauma and perioperative settings. Compared with regional competitors, Grifols benefits from stronger brand recognition and a diversified geographic mix, which mitigates reimbursement risk in any single country and supports long-term contract stability.

4. LFB S.A.:

   LFB S.A. has a specialized position in the fibrinogen concentrates market, with a strong base in France and broader reach into select European and Middle Eastern markets through public tenders and hospital collaborations. Its historical focus on plasma-derived products for rare diseases and critical care has enabled the company to build trust with clinicians managing complex coagulation disorders and obstetric hemorrhage.

   In 2025, LFB’s fibrinogen concentrates revenue is estimated at EUR 0.06 Billion with a corresponding global market share of about 5.80% . This scale reflects a mid-tier position with strong national dominance but more limited global penetration when compared with the largest multinational plasma players. The revenue base still allows LFB to sustain targeted research collaborations, invest in production modernization, and defend its share in key domestic and regional markets.

   LFB’s competitive differentiation arises from its close alignment with public healthcare systems, its experience in delivering products under stringent national blood policies, and its tailored support for hospital transfusion committees. The company often competes effectively in tenders that prioritize quality, traceability, and domestic supply security. However, its smaller international presence relative to global giants means that future growth will depend on partnerships, co-marketing arrangements, and careful selection of high-value export markets where regulatory and tender barriers are manageable.

5. Takeda Pharmaceutical Company Limited:

   Takeda Pharmaceutical Company Limited participates in the fibrinogen concentrates segment as part of its broader rare disease and plasma-derived therapies portfolio. While fibrinogen is not its largest product category, it fits strategically with Takeda’s focus on hematology, immunology, and specialty care, enabling comprehensive support for complex bleeding disorders. The company’s strong footprint in Japan, North America, and Europe provides a platform to scale fibrinogen concentrates in both established and selectively targeted growth markets.

   For 2025, Takeda’s fibrinogen concentrates revenue is projected at USD 0.09 Billion with an estimated market share of 8.40% . These figures illustrate a competitive but not dominant positioning, with fibrinogen contributing meaningfully to Takeda’s plasma portfolio but remaining a smaller component of its total corporate revenue. The market share nonetheless enables Takeda to influence clinical protocols and engage in multi-product contracting with large hospital systems.

   Takeda’s strategic strength lies in its global regulatory maturity, strong pharmacovigilance systems, and extensive relationships with key opinion leaders in hematology and surgery. The company differentiates itself through evidence-based positioning of fibrinogen concentrates in perioperative blood management and through integrated care models that combine plasma products, diagnostics, and patient-support programs. Compared to pure-play plasma firms, Takeda can also leverage its broader pipeline and R&D capabilities, which may support combination strategies, data-driven value-based contracts, and technology upgrades in manufacturing over the medium term.

6. Pfizer Inc.:

   Pfizer Inc. is a diversified biopharmaceutical leader whose exposure to the fibrinogen concentrates market is part of a broader strategic interest in hospital acute care, hematology, and perioperative medicine. Although fibrinogen concentrates are a relatively small slice of Pfizer’s portfolio compared with its vaccines and oncology assets, the company’s global commercial infrastructure allows it to deploy hospital sales forces and market-access capabilities efficiently where fibrinogen offerings are available.

   In 2025, Pfizer’s fibrinogen-related revenue is estimated at USD 0.04 Billion with a market share of around 3.80% . This reflects a niche but strategically significant presence, especially in markets where Pfizer’s hospital relationships are strong and procedural volumes for high-risk surgeries are large. The relatively modest market share underscores that Pfizer is not a volume leader in fibrinogen concentrates but can still shape purchasing decisions via cross-portfolio negotiations.

   Pfizer’s advantages include world-class clinical development experience, sophisticated health economic modeling, and established pathways for market access and reimbursement discussions. The company can integrate fibrinogen concentrates into perioperative care bundles or enhanced recovery pathways promoted to hospital systems. Compared to specialist plasma companies, Pfizer has less legacy dependence on plasma fractionation, which could allow flexible partnering, licensing, or co-development arrangements if it chooses to expand its role in this segment in response to rising global demand.

7. Bio Products Laboratory Ltd (BPL):

   Bio Products Laboratory Ltd (BPL) has a focused presence in the fibrinogen concentrates market, with historical roots in the United Kingdom’s plasma-derived therapies sector and a growing international footprint. The company targets specialized indications and seeks to differentiate itself through product reliability, traceability, and clinically relevant dosing options tailored to intensive care and surgical settings.

   For 2025, BPL’s fibrinogen concentrates revenue is projected at USD 0.05 Billion and a market share of approximately 4.70% . This positions BPL as a smaller but credible competitor, especially in markets where clinicians value its long-standing expertise in plasma products and trust its quality standards. The revenue base is sufficient to support incremental capacity investments and selective geographic expansion, though not on the scale of the largest global players.

   BPL’s strategic strengths include its heritage in national blood services, emphasis on manufacturing robustness, and strong pharmacovigilance practices. The company often focuses on partnership-driven growth, engaging distributors and local agents in regions where direct commercial presence would be cost-prohibitive. Compared to larger competitors, BPL can be more agile in responding to niche clinical needs, such as tailored packaging formats or educational materials targeted at specific hospital specialties managing severe bleeding complications.

8. Kedrion Biopharma Inc.:

   Kedrion Biopharma Inc. is an important mid-sized player in the global fibrinogen concentrates arena, with core operations in Italy and a growing footprint in North America and selected emerging markets. The company’s mission centers on plasma-derived therapies for rare disorders and critical care, making fibrinogen concentrates a strategically aligned product category for both congenital and acquired fibrinogen deficiencies.

   In 2025, Kedrion’s fibrinogen concentrates revenue is estimated at EUR 0.06 Billion with a global market share of roughly 5.40% . These figures reflect a robust regional position and a gradually expanding global presence, especially in markets where Kedrion has secured regulatory approvals and built relationships with national blood authorities. The company’s share suggests meaningful competitiveness in tenders while still leaving room for further international growth.

   Kedrion’s competitive differentiation comes from its close partnerships with public health systems, strong capabilities in plasma collection and fractionation, and a portfolio focused on unmet medical needs. The company often capitalizes on opportunities in countries transitioning from cryoprecipitate to standardized fibrinogen concentrates, offering training and support for clinical teams. Relative to larger multinationals, Kedrion can be more flexible in pricing structures and contract terms, which can be an advantage when entering price-sensitive markets or supporting pilot programs in trauma and obstetric hemorrhage management.

9. China Biologic Products Holdings Inc.:

   China Biologic Products Holdings Inc. is a leading domestic plasma-derived product manufacturer in China, where demand for fibrinogen concentrates is rising due to growth in advanced surgical procedures and the modernization of transfusion medicine. The company primarily serves the Chinese market, which provides a large patient base and increasing adoption of evidence-based hemostasis protocols.

   For 2025, China Biologic’s fibrinogen concentrates revenue is projected at CNY 0.07 Billion with a global market share estimated at 3.90% . While this global share appears modest, the company’s domestic position is considerably stronger because much of its sales volume is concentrated in China rather than distributed worldwide. The revenue enables continued modernization of local plasma collection infrastructure and investment in quality systems that align with evolving Chinese regulatory standards.

   The company’s strategic advantages include strong distribution networks within China, local regulatory familiarity, and alignment with national healthcare policy priorities emphasizing domestic production of essential biologics. China Biologic differentiates itself through its ability to meet localized demand, manage regional tender processes, and adapt packaging or logistics to the specific needs of Chinese hospitals. Compared with global competitors, it is uniquely positioned to navigate provincial-level reimbursement structures and hospital formulary decisions within China’s rapidly evolving healthcare landscape.

10. Sanquin:

    Sanquin operates as a not-for-profit blood supply organization with commercial activities in plasma-derived products, including fibrinogen concentrates. Its primary strength lies in the Netherlands, where it manages blood collection and production, and in selected export markets where its high-quality standards and scientific reputation are recognized. Sanquin plays an important role in shaping clinical protocols and research in coagulation management within its home market.

    In 2025, Sanquin’s fibrinogen concentrates revenue is estimated at EUR 0.03 Billion with a global market share of around 2.40% . This reflects a niche but influential position, particularly considering Sanquin’s strong integration with national healthcare policy and academic research. While its global revenue scale is limited, its impact on national practice patterns and its reputation for quality provide outsized strategic relevance.

    Sanquin’s competitive advantages include its deep integration with a national blood service, strong links to academic hospitals, and continuous involvement in clinical research on hemostasis and transfusion alternatives. The organization differentiates itself by emphasizing scientific evidence, quality, and patient safety rather than pure commercial expansion. Compared with fully commercial entities, Sanquin’s model enables long-term investments in research and quality improvements that may not immediately translate into global market share but do influence broader clinical thinking about fibrinogen concentrate use.

11. Shanghai RAAS Blood Products Co. Ltd.:

    Shanghai RAAS Blood Products Co. Ltd. is a key Chinese plasma-derived therapies company with a growing focus on fibrinogen concentrates as demand increases for standardized coagulation management in Chinese hospitals. The company benefits from proximity to a large patient population, expanding surgical services, and the gradual shift away from less standardized blood components toward purified coagulation factors.

    For 2025, Shanghai RAAS’s fibrinogen concentrates revenue is projected at CNY 0.06 Billion and a global market share of approximately 3.40% . This market share is primarily driven by domestic sales and reflects a meaningful role in China’s internal market while contributing a smaller share to the global total. The revenue allows the company to invest in capacity upgrades, cold-chain logistics, and compliance with evolving national and international regulatory standards.

    Shanghai RAAS’s strategic strengths include strong local regulatory knowledge, broad provincial distribution networks, and an ability to adapt product offerings to local clinical practices. The company differentiates itself within China through quality improvements, marketing to tertiary hospitals, and participation in education efforts around modern transfusion and coagulation management. Compared to multinational entrants, Shanghai RAAS enjoys advantages in navigating local tender processes, managing regional relationships, and responding quickly to policy changes that influence reimbursement for plasma-derived therapies.

12. Green Cross Corporation:

    Green Cross Corporation, based in South Korea, is an established producer of plasma-derived products and vaccines, and it maintains a growing presence in fibrinogen concentrates. The company serves the domestic Korean market and exports to select international destinations where its products meet regulatory and quality requirements. Fibrinogen concentrates augment its broader critical care and hematology portfolio.

    In 2025, Green Cross’s fibrinogen concentrates revenue is estimated at KRW 0.04 Billion with a global market share of roughly 2.90% . This indicates a modest but strategically relevant role in the global market, with stronger relative positioning in its home country. The revenue contribution, while not large compared to global leaders, supports ongoing investment in manufacturing and in the expansion of regulatory approvals in new export markets.

    Green Cross’s competitive advantages include its strong domestic brand, integrated R&D and manufacturing capabilities, and experience working within stringent Korean regulatory frameworks. The company differentiates itself through reliability of supply in its home market and through incremental geographic expansion focused on regions where regulatory pathways and demand conditions are favorable. Compared to some larger global firms, Green Cross can prioritize regional specialization and cost-efficient operations, which is attractive to mid-sized hospitals and government buyers in price-sensitive markets.

13. Biotest AG:

    Biotest AG is a German-based specialist in plasma-derived and immunology products, and fibrinogen concentrates represent an important component of its hemostasis portfolio. The company has a well-established presence in Europe and selected international markets, focusing on hospitals and clinics that require high-quality plasma products for complex bleeding and immune-related disorders.

    For 2025, Biotest’s fibrinogen concentrates revenue is projected at EUR 0.05 Billion and a global market share of about 4.20% . These figures point to a solid mid-tier position in the global market, with particular strength in European healthcare systems where Biotest’s relationships and regulatory history are long-standing. The revenue base supports targeted R&D, process optimization, and selective expansion into promising new markets.

    Biotest’s strategic strengths lie in its scientific expertise, manufacturing excellence, and close collaboration with clinicians managing immune and coagulation disorders. The company differentiates itself through a focused portfolio, strong quality systems, and an emphasis on clinical support and training for healthcare professionals. Compared with larger, more diversified competitors, Biotest can allocate a higher relative priority to optimizing its fibrinogen products, enhancing its responsiveness to evolving clinical evidence and guideline changes in trauma and perioperative blood management.

14. Hualan Biological Engineering Inc.:

    Hualan Biological Engineering Inc. is a prominent Chinese biopharmaceutical company engaged in plasma-derived products and vaccines, with fibrinogen concentrates emerging as a growing product category. The company leverages China’s expanding healthcare infrastructure and rising demand for advanced hemostasis solutions in trauma, obstetrics, and high-risk surgery.

    In 2025, Hualan’s fibrinogen concentrates revenue is estimated at CNY 0.05 Billion and a global market share of approximately 2.80% . While this translates into a modest share of the global market, it represents a meaningful position within China’s domestic fibrinogen landscape, where overall demand is accelerating. The revenue supports ongoing investment in quality upgrades, facility expansion, and R&D to align with international best practices.

    Hualan’s competitive differentiation comes from its integration into China’s healthcare ecosystem, its growing R&D capabilities, and its willingness to invest in newer plasma technologies. The company focuses on meeting domestic demand first but may gradually increase its international presence as its quality systems and regulatory credentials advance. Compared to global incumbents, Hualan has a stronger understanding of local hospital procurement behavior and can fine-tune its market-access strategies to fit provincial policies and hospital budget constraints.

15. Prothya Biosolutions:

    Prothya Biosolutions is a European plasma-derived therapies company formed through the combination of regional plasma operations, and it maintains a targeted presence in fibrinogen concentrates. Its activities are particularly relevant in the Benelux and selected European markets where it supplies hospitals with a range of coagulation and immunoglobulin products. Fibrinogen concentrates strengthen its hemostasis portfolio and support its positioning as a specialized plasma partner for regional healthcare systems.

    In 2025, Prothya’s fibrinogen concentrates revenue is projected at EUR 0.03 Billion with an estimated global market share of 2.10% . This reflects a focused, niche presence, with most revenue derived from a limited set of European markets rather than broad global penetration. The revenue scale is sufficient to maintain high-quality manufacturing operations and to support selective investments in process improvements and regulatory compliance initiatives.

    Prothya’s strategic advantages include its regional roots, close collaboration with national blood authorities, and a strong emphasis on supply security and quality. The company differentiates itself by offering reliable access to essential plasma-derived products, including fibrinogen concentrates, to healthcare systems that value local or regional suppliers. Compared with much larger multinationals, Prothya can be more responsive to local stakeholder needs and is well-positioned to participate in long-term supply agreements that prioritize resilience and traceability over purely lowest-cost purchasing.